Dishman Carbogen Amcis Ltd
NSE: DCAL BSE: 540701
₹158.05
(-1.42%)
Mon, 23 Mar 2026, 11:33 am
Market Cap24.87B
PE Ratio20.86
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KDishman Carbogen Amcis Analysis
dividend
- Dishman Carbogen Amcis is not paying a notable dividend for India, therefore no need to check if the payments are increasing.
- No need to calculate the sustainability of Dishman Carbogen Amcis's dividends as it is not paying a notable one for India.
- Dishman Carbogen Amcis is not paying a notable dividend for India, therefore no need to check if the payments are stable.
- Dishman Carbogen Amcis's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Dishman Carbogen Amcis's dividend is below the markets top 25% of dividend payers in India (3.08%).
future
- Dishman Carbogen Amcis's earnings growth is expected to exceed the low risk savings rate of 7.2%.
- An improvement in Dishman Carbogen Amcis's performance (ROE) is expected over the next 3 years.
- Dishman Carbogen Amcis's revenue growth is expected to exceed the India market average.
- Cash flow for Dishman Carbogen Amcis is expected to decrease over the next 2 years.
- Dishman Carbogen Amcis's earnings are expected to grow by 14.9% yearly, however this is not considered high growth (20% yearly).
- Dishman Carbogen Amcis's earnings growth is positive but not above the India market average.
- Dishman Carbogen Amcis's earnings are expected to decrease over the next year.
- Dishman Carbogen Amcis's net income is expected to increase but not above the 50% threshold in 2 years time.
- Dishman Carbogen Amcis is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
- Performance (ROE) is not expected to exceed the current IN Life Sciences industry average.
- Dishman Carbogen Amcis's revenue is expected to increase but not above the 50% threshold in 2 years time.
- Dishman Carbogen Amcis's revenue is expected to grow by 7.7% yearly, however this is not considered high growth (20% yearly).
health
- Dishman Carbogen Amcis is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Dishman Carbogen Amcis is profitable, therefore cash runway is not a concern.
- Dishman Carbogen Amcis is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (63%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 1.9x debt.
- Dishman Carbogen Amcis's cash and other short term assets cover its long term commitments.
- Dishman Carbogen Amcis had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
- Interest payments on debt are well covered by earnings (EBIT is 3.9x coverage).
- Dishman Carbogen Amcis's level of debt (16.2%) compared to net worth is satisfactory (less than 40%).
- High level of physical assets or inventory.
management
- The tenure for the Dishman Carbogen Amcis board of directors is about average.
- Arpit's remuneration is lower than average for companies of similar size in India.
- Arpit's compensation has been consistent with company performance over the past year, both up more than 20%.
- More shares have been bought than sold by Dishman Carbogen Amcis individual insiders in the past 3 months.
misc
- Dishman Carbogen Amcis has significant price volatility in the past 3 months.
past
- Dishman Carbogen Amcis has delivered over 20% year on year earnings growth in the past 5 years.
- Dishman Carbogen Amcis's 1-year earnings growth is negative, it can't be compared to the 5-year average.
- Dishman Carbogen Amcis used its assets less efficiently than the IN Life Sciences industry average last year based on Return on Assets.
- Dishman Carbogen Amcis's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- Dishman Carbogen Amcis has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Dishman Carbogen Amcis's 1-year earnings growth is negative, it can't be compared to the IN Life Sciences industry average.
value
- Dishman Carbogen Amcis is good value based on assets compared to the IN Life Sciences industry average.
- Dishman Carbogen Amcis is good value based on expected growth next year.
- Dishman Carbogen Amcis is good value based on earnings compared to the IN Life Sciences industry average.
- NSEI:DCAL is up 74.3% outperforming the Life Sciences industry which returned 2.6% over the past month.
- NSEI:DCAL is up 74.3% outperforming the market in India which returned 8% over the past month.
- Dishman Carbogen Amcis's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Dishman Carbogen Amcis's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Dishman Carbogen Amcis is overvalued based on earnings compared to the India market.
- DCAL underperformed the Life Sciences industry which returned 36.1% over the past year.
- DCAL underperformed the Market in India which returned -14.5% over the past year.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800